Search

Your search keyword '"Izumiya, Yasuhiro"' showing total 800 results
Start Over Author "Izumiya, Yasuhiro"
800 results on '"Izumiya, Yasuhiro"'

3. Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial)

Author

Ito, Shin, Nakajima, Yuri, Fukuda, Hiroki, Izumi, Chisato, Nakazawa, Gaku, Yamashita, Hajime, Matsuhisa, Hideo, Inoko, Moriaki, Toyoda, Shigeru, Takiuchi, Shin, Kataoka, Toru, Izumiya, Yasuhiro, Abe, Yukio, Sozu, Takashi, Sakata, Yasushi, Emoto, Masanori, Inoue, Teruo, and Kitakaze, Masafumi

Published
2024
Full Text
View/download PDF

7. Mosaic Loss of the Y Chromosome Is Enriched in Patients With Wild-Type Transthyretin Cardiac Amyloidosis and Associated With Increased Mortality

Author

Thel, Mark C., Cochran, Jesse D., Teruya, Sergio, Hayashi, Ou, Xie, Christopher R., Srinivasan, Ajay R., Chavkin, Nicholas W., Arai, Yohei, Sano, Soichi, Mirabal Santos, Alfonsina, De Los Santos, Jeffeny, Fine, Denise, Sabogal, Natalia, Ullah, Ikram, Helmke, Stephen, Rodriguez, Carlos, Prokaeva, Tatiana, Foster, Rachel H., Spencer, Brian H., Izumiya, Yasuhiro, Maurer, Mathew S., Walsh, Kenneth, and Ruberg, Frederick L.

Published
2024
Full Text
View/download PDF

15. Real-World Management of Pharmacological Thromboprophylactic Strategies for COVID-19 Patients in Japan: From the CLOT-COVID Study

Author

Hayashi, Hiroya, Izumiya, Yasuhiro, Fukuda, Daiju, Wakita, Fumiaki, Mizobata, Yasumitsu, Fujii, Hiromichi, Yachi, Sen, Takeyama, Makoto, Nishimoto, Yuji, Tsujino, Ichizo, Nakamura, Junichi, Yamamoto, Naoto, Nakata, Hiroko, Ikeda, Satoshi, Umetsu, Michihisa, Aikawa, Shizu, Satokawa, Hirono, Okuno, Yoshinori, Iwata, Eriko, Ogihara, Yoshito, Ikeda, Nobutaka, Kondo, Akane, Iwai, Takehisa, Yamada, Norikazu, Ogawa, Tomohiro, Kobayashi, Takao, Mo, Makoto, and Yamashita, Yugo

Published
2022
Full Text
View/download PDF

19. Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan.

Author

Kato, Takao, Ines, Monica, Minamisawa, Masatoshi, Benjumea, Darrin, Keohane, Denis, Alvir, Jose, Kim, Ruth, Chen, Yong, Peixoto, Telma, Kent, Matthew, Wogen, Jenifer, Ishii, Tomonori, Crowley, Aaron, Sugino, Toshiya, and Izumiya, Yasuhiro

Subjects
PATIENT compliance, ANGIOTENSIN-receptor blockers, HEART failure patients, HEART diseases, DATABASES, HEART failure
Abstract

Aims: This study aimed to describe baseline characteristics and adherence among patients with transthyretin amyloid cardiomyopathy (ATTR‐CM) treated with tafamidis (VYNDAQEL®) in Japan using the Japanese Medical Data Vision (MDV) database. Methods and results: This study was a non‐interventional, retrospective cohort study of adult (≥18 years old) patients in the Japanese MDV claims database diagnosed with ATTR‐CM and with at least two tafamidis prescriptions of dose strength 4 × 20 mg/day between 1 March 2019 and 31 August 2021. The date of the first prescription was defined as the index date, with follow‐up time defined as the time between the first and last prescription plus the days' supply from the last refill. Baseline characteristics were assessed during a 12 month pre‐index period. Adherence was measured using two metrics: (i) the modified medication possession ratio (mMPR), calculated by taking the sum of days supplied for all fills within the follow‐up period, divided by the number of days of follow‐up, and reported as a percentage, with patients classified as adherent with an mMPR of ≥80%, and (ii) the proportion of days covered (PDC), calculated by taking the total number of days' supply dispensed during the follow‐up period divided by the number of days of follow‐up, adjusting for any days' supply overlap. A total of 210 patients were identified; the mean (standard deviation) age of the cohort was 77 (5.9) years, and the majority (89%) were male. The most common baseline cardiovascular comorbidities were heart failure (85%), ischaemic heart disease (66%), hypertensive diseases (49%), and diabetes (35%); 75% of patients received heart failure medications in the 12 months prior to index, with the most common being beta‐blockers (49%), diuretics (48%), angiotensin receptor blockers (30%), angiotensin‐converting enzyme inhibitors (22%), and sodium–glucose cotransporter‐2 inhibitors (8.1%). Over an average 14 month follow‐up, mean mMPR was 96% with a median of 100% [inter‐quartile range (IQR): 97–101%]; 93% of patients were adherent (defined as an mMPR ≥ 80%). In the same follow‐up period, mean PDC was 93.6% with a median of 99% (IQR: 93–100%). Persistence was high with 78% of patients having a 0 day gap between prescription refills. Conclusions: This study found high adherence rates to tafamidis in this real‐world Japanese patient population. Adherence rates in this study were similar to those reported by the tafamidis clinical trial and a previously published US commercial claims adherence analysis. Further studies should be conducted to assess the impact of real‐world adherence on real‐world outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Murine neonatal ketogenesis preserves mitochondrial energetics by preventing protein hyperacetylation

Author

Arima, Yuichiro, Nakagawa, Yoshiko, Takeo, Toru, Ishida, Toshifumi, Yamada, Toshihiro, Hino, Shinjiro, Nakao, Mitsuyoshi, Hanada, Sanshiro, Umemoto, Terumasa, Suda, Toshio, Sakuma, Tetsushi, Yamamoto, Takashi, Watanabe, Takehisa, Nagaoka, Katsuya, Tanaka, Yasuhito, Kawamura, Yumiko K., Tonami, Kazuo, Kurihara, Hiroki, Sato, Yoshifumi, Yamagata, Kazuya, Nakamura, Taishi, Araki, Satoshi, Yamamoto, Eiichiro, Izumiya, Yasuhiro, Sakamoto, Kenji, Kaikita, Koichi, Matsushita, Kenichi, Nishiyama, Koichi, Nakagata, Naomi, and Tsujita, Kenichi

Published
2021
Full Text
View/download PDF

28. Correction: Tissue responses to everolimus-eluting stents implanted in severely calcified lesions following atherectomy

Author

Yamaguchi, Tomohiro, primary, Yamazaki, Takanori, additional, Yoshida, Hisako, additional, Matsumoto, Kotaro, additional, Yahiro, Ryosuke, additional, Nakao, Kazuhiro, additional, Kure, Yusuke, additional, Okai, Tsukasa, additional, Shimada, Takenobu, additional, Otsuka, Kenichiro, additional, Izumiya, Yasuhiro, additional, and Fukuda, Daiju, additional

Published
2023
Full Text
View/download PDF

29. Fetal Origins of Hypertension

Author

Arima, Yuichiro, Nishiyama, Koichi, Izumiya, Yasuhiro, Kaikita, Koichi, Hokimoto, Seiji, Tsujita, Kenichi, COHEN, IRUN R., Series Editor, LAJTHA, ABEL, Series Editor, LAMBRIS, JOHN D., Series Editor, PAOLETTI, RODOLFO, Series Editor, REZAEI, NIMA, Series Editor, Kubota, Takeo, editor, and Fukuoka, Hideoki, editor

Published
2018
Full Text
View/download PDF

30. Elevation of end-tidal CO2 during exercise is attenuated in patients with cardiac amyloidosis.

Author

Shibata, Atsushi, Izumiya, Yasuhiro, Yoshida, Toshitake, Tanihata, Akiko, Yamaguchi, Yumi, Kitada, Ryoko, and Fukuda, Daiju

Subjects
*CARDIAC amyloidosis, *EXERCISE tolerance, *CARDIAC patients, *EXERCISE tests, *PROPENSITY score matching, *HEART failure patients
Abstract

Reduced exercise tolerance is one of the hallmarks of patients with cardiac amyloidosis (CA), but detailed biological responses during exercise were not investigated. The purpose of this study was to compare the cardiopulmonary exercise test (CPX) parameters between CA patients and propensity-matched heart failure patients. This was a single-center, retrospective, observational study of patients diagnosed with CA. The control group was extracted by propensity score matching from patients who underwent CPX for chronic heart failure during the same period. Clinical data including assessment of biological responses during CPX were compared between the patients with CA (CA group, n = 16) and the control group (non-CA group, n = 16). Echocardiography suggested more impaired diastolic function in the CA group than in the non-CA group. There was no significant difference between groups in the fraction of end-tidal carbon dioxide (FETCO2) at rest. However, the difference between the FETCO2 at rest and the FETCO2 at the respiratory compensation point (ΔFETCO2) was significantly smaller in the CA group than in the non-CA group (0.40% ± 0.37% vs. 0.82% ± 0.33%; p = 0.002). Only in the CA group, there was a significant negative correlation between the ΔFETCO2 and the E/e' ratio on echocardiography (r = − 0.521; p = 0.039) and the serum high-sensitivity troponin T concentration (r = − 0.501; p = 0.048). In conclusion, patients with CA may find it difficult to increase cardiac output during exercise due to severe diastolic dysfunction. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Quantification of pulmonary perfusion using LSIM-CT correlates with pulmonary hemodynamics in patients with CTEPD

Author

Yamaguchi, Tomohiro, primary, Ehara, Shoichi, additional, Yoshida, Hisako, additional, Himoto, Daisuke, additional, Izuta, Shinichiro, additional, Hayashi, Ou, additional, Hayashi, Hiroya, additional, Ogawa, Mana, additional, Shibata, Atsushi, additional, Yamazaki, Takanori, additional, Izumiya, Yasuhiro, additional, and Fukuda, Daiju, additional

Published
2023
Full Text
View/download PDF

34. Thrombus or tumor?

Author

Wakasa, Shiho, primary, Hayashi, Hiroya, additional, Yamazaki, Takanori, additional, Izumiya, Yasuhiro, additional, and Fukuda, Daiju, additional

Published
2023
Full Text
View/download PDF

36. Non-invasive testing for sarcopenia predicts future cardiovascular events in patients with chronic kidney disease

Author

Hanatani, Shinsuke, Izumiya, Yasuhiro, Onoue, Yoshiro, Tanaka, Tomoko, Yamamoto, Masahiro, Ishida, Toshifumi, Yamamura, Satoru, Kimura, Yuichi, Araki, Satoshi, Arima, Yuichiro, Nakamura, Taishi, Fujisue, Koichiro, Takashio, Seiji, Sueta, Daisuke, Sakamoto, Kenji, Yamamoto, Eiichiro, Kojima, Sunao, Kaikita, Koichi, and Tsujita, Kenichi

Published
2018
Full Text
View/download PDF

37. Impact of Chronic Kidney Disease on Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusions (from the Japanese Multicenter Registry)

Author

Naganuma, Toru, Tsujita, Kenichi, Mitomo, Satoru, Ishiguro, Hisaaki, Basavarajaiah, Sandeep, Sato, Katsumasa, Kobayashi, Tsuyoshi, Obata, Junei, Nagamatsu, Suguru, Yamanaga, Kenshi, Komura, Naohiro, Sakamoto, Kenji, Yamamoto, Eiichiro, Izumiya, Yasuhiro, Kojima, Sunao, Kaikita, Koichi, Ogawa, Hisao, and Nakamura, Sunao

Published
2018
Full Text
View/download PDF

40. Correlation between Low Amount of Epicardial Adipose Tissue and the Severity of Right Ventricular Dysfunction in Patients with Nonischemic Heart Failure with Reduced Ejection Fraction

Author

Tanihata, Akiko, Ehara, Shoichi, Kitada, Ryoko, Ishikawa, Hirotoshi, Yoshida, Toshitake, Hayashi, Hiroya, Yamaguchi, Yumi, Shibata, Atsushi, Izumiya, Yasuhiro, and Fukuda, Daiju

Subjects
Epicardial adipose tissue, Heart failure, Magnetic resonance imagingMagnetic resonance imaging, Right ventricular failure
Abstract

Background : Although epicardial adipose tissue (EAT) volume is associated with coronary artery disease and atrial fibrillation, the clinical role of EAT in heart failure (HF) remains controversial. In patients with HF with reduced ejection fraction (HFrEF), right ventricular (RV) dysfunction is associated with impaired functional capacity. This study aimed to investigate the relationship between the EAT volume and RV systolic function in patients with HFrEF.

Published
2022

44. Cardiomyocyte Sirt (Sirtuin) 7 Ameliorates Stress-Induced Cardiac Hypertrophy by Interacting With and Deacetylating GATA4

Author

Yamamura, Satoru, Izumiya, Yasuhiro, Araki, Satoshi, Nakamura, Taishi, Kimura, Yuichi, Hanatani, Shinsuke, Yamada, Toshihiro, Ishida, Toshifumi, Yamamoto, Masahiro, Onoue, Yoshiro, Arima, Yuichiro, Yamamoto, Eiichiro, Sunagawa, Yoichi, Yoshizawa, Tatsuya, Nakagata, Naomi, Bober, Eva, Braun, Thomas, Sakamoto, Kenji, Kaikita, Koichi, Morimoto, Tatsuya, Yamagata, Kazuya, and Tsujita, Kenichi

Published
2020
Full Text
View/download PDF

45. A retrospective study of arterial stiffness and subsequent clinical outcomes in cancer patients undergoing percutaneous coronary intervention

Author

Tabata, Noriaki, Sueta, Daisuke, Yamamoto, Eiichiro, Takashio, Seiji, Arima, Yuichiro, Araki, Satoshi, Yamanaga, Kenshi, Ishii, Masanobu, Sakamoto, Kenji, Kanazawa, Hisanori, Fujisue, Koichiro, Hanatani, Shinsuke, Soejima, Hirofumi, Hokimoto, Seiji, Izumiya, Yasuhiro, Kojima, Sunao, Yamabe, Hiroshige, Kaikita, Koichi, Matsui, Kunihiko, and Tsujita, Kenichi

Published
2019
Full Text
View/download PDF

46. A case of hypertrophic cardiomyopathy with right ventricular outflow tract and left midventricular obstruction

Author

Okada, Natsumi, Shibata, Atsushi, Tanihata, Akiko, Kitada, Ryoko, Ehara, Shoichi, and Izumiya, Yasuhiro

Subjects
Case Report, Cardiology and Cardiovascular Medicine
Abstract

We describe a case of a 59-year-old woman with hypertrophic cardiomyopathy who remained with right ventricular outflow tract obstruction after the pressure gradient in the left midventricle was resolved by a drug with a negative inotropic effect. The patient was diagnosed with hypertrophic cardiomyopathy 30 years previously and was only on low-dose beta-blocker therapy. She presented at our hospital with suspected exacerbation of heart failure because of the development and exacerbation of dyspnea and chest tightness. Transthoracic echocardiography showed an accelerated blood flow of 3 m/s in the middle of the left ventricle; thus, she was started on cibenzoline, a drug with a negative inotropic effect. After admission, intracardiac pressure measurement showed no pressure gradient in the left chamber. However, there was a pressure gradient of 18 mmHg between the apex of the right ventricle and the right ventricular outflow tract, and right ventricular outflow tract obstruction was confirmed on cardiac magnetic resonance imaging. We decided to reinforce the negative inotropic effect by adding bisoprolol, and the subjective symptoms and auscultatory systolic murmur were eliminated 2 months later. LEARNING OBJECTIVE: Hypertrophy of the right ventricular myocardium can occur in patients with hypertrophic cardiomyopathy (HCM). However, right ventricular outflow tract obstruction remains a rare finding in patients with HCM, despite the presence of morphological abnormalities such as right ventricular hypertrophy. In patients with HCM, obstruction of the right ventricle should be considered if the symptoms and auscultatory findings do not match the left ventricular imaging findings.

Published
2022

47. Impact of cystatin C-derived glomerular filtration rate in patients undergoing transcatheter aortic valve implantation

Author

Kure, Yusuke, primary, Okai, Tsukasa, additional, Izumiya, Yasuhiro, additional, Yoshida, Hisako, additional, Mizutani, Kazuki, additional, Yamaguchi, Tomohiro, additional, Ogawa, Mana, additional, Shibata, Atsushi, additional, Ito, Asahiro, additional, Takahashi, Yosuke, additional, Shibata, Toshihiko, additional, and Fukuda, Daiju, additional

Published
2023
Full Text
View/download PDF

49. Tricuspid Annular Area and Leaflets Stretch are Associated with Functional Tricuspid Regurgitation – Insights from Three-Dimensional Transesophageal Echocardiography –

Author

Ogawa, Mana, primary, Ito, Asahiro, additional, Ito, Ayaka, additional, Kim, Andrew T, additional, Ishikawa, Sera, additional, Iwata, Shinichi, additional, Takahashi, Yosuke, additional, Izumiya, Yasuhiro, additional, Shibata, Toshihiko, additional, and Fukuda, Daiju, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results